Hazlett Burt & Watson Inc. Increases Position in Danaher Co. (NYSE:DHR)

Hazlett Burt & Watson Inc. increased its stake in Danaher Co. (NYSE:DHR) by 4,761.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,021 shares of the conglomerate’s stock after purchasing an additional 1,000 shares during the quarter. Hazlett Burt & Watson Inc.’s holdings in Danaher were worth $256,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Patrick M Sweeney & Associates Inc. increased its stake in shares of Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after buying an additional 40 shares during the last quarter. Trust Co of Kansas boosted its holdings in Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after purchasing an additional 40 shares during the period. Abacus Planning Group Inc. boosted its holdings in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after purchasing an additional 40 shares during the period. ST Germain D J Co. Inc. boosted its holdings in Danaher by 1.4% in the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after purchasing an additional 41 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its holdings in Danaher by 1.8% in the second quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after purchasing an additional 42 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on DHR shares. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Evercore ISI decreased their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. TD Cowen boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Bank of America boosted their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Stock Up 0.6 %

DHR stock opened at $274.72 on Wednesday. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company’s 50 day simple moving average is $262.56 and its 200-day simple moving average is $256.11. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market capitalization of $198.41 billion, a P/E ratio of 46.56, a P/E/G ratio of 4.38 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.